Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	118.78	118.32	151.89
Short-Term Investments	407.27	277.14	-
Cash & Short-Term Investments	526.05	395.46	151.89
Cash Growth	24.40%	160.36%	-
Prepaid Expenses	3.27	1.74	0.11
Other Current Assets	0.4	1.21	0.06
Total Current Assets	534.48	398.41	152.06
Property, Plant & Equipment	13.54	2.59	-
Other Long-Term Assets	0.51	0.4	-
Total Assets	776.29	401.4	152.06
Accounts Payable	2.22	2.14	0.42
Accrued Expenses	27.53	17.31	9.56
Current Portion of Leases	2.87	1.1	-
Total Current Liabilities	32.61	20.56	9.98
Long-Term Leases	9.27	0.93	-
Total Liabilities	41.88	21.49	9.98
Common Stock	0	-	2.25
Additional Paid-In Capital	969.83	503.35	-
Retained Earnings	-238.7	-123.77	-39.79
Comprehensive Income & Other	3.27	0.33	2.14
Total Common Equity	734.4	379.91	-35.39
Shareholders' Equity	734.4	379.91	142.08
Total Liabilities & Equity	776.29	401.4	152.06
Total Debt	12.14	2.03	-
Net Cash (Debt)	741.66	393.43	151.89
Net Cash Growth	75.39%	159.02%	-
Net Cash Per Share	14.00	15.73	61.69
Filing Date Shares Outstanding	56.9	48.52	5
Total Common Shares Outstanding	56.9	48.52	5
Working Capital	501.87	377.85	142.08
Book Value Per Share	12.91	7.83	-7.08
Tangible Book Value	734.4	379.91	-35.39
Tangible Book Value Per Share	12.91	7.83	-7.08

Source: S&P Capital IQ. Standard template. Financial Sources.